Abstract 1247P – PACIFIC-R

Since the publication of the PACIFIC trial, chemoradiotherapy followed by consolidation durvalumab has become standard of care for patients with unresectable, stage III non-small cell lung cancer (NSCLC). Subsequently, the PACIFIC-R study was set up to evaluate how this treatment regimen performs in a real-world setting. The study was conducted across 290 sites in France, Spain, Australia, The Netherlands, Belgium, Italy, Israel, Germany, the UK, Norway and Switzerland. As pneumonitis is a common adverse event in NSCLC patients treated with a combination of radiotherapy and immune checkpoint inhibition, PACIFIC-R researchers also evaluated whether certain treatment patterns or baseline characteristics were associated with the development of symptomatic pneumonitis. The results of this analysis were presented as a poster at ESMO 2024 by Prof Dr Andrea Filippi, Radiation Oncologist at the Università degli studi in Milan, Italy. This analysis revealed a real-world incidence of symptomatic pneumonitis of 19.4%. In this respect, the presence of chronic obstructive pulmonary disease (COPD) at baseline and a higher mean dose of radiotherapy to the lung were associated with a higher likelihood for the development of symptomatic pneumonitis. As such, these findings underscore the importance for strategic radiotherapy planning in this patients with unresectable stage III NSCLC.